3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Neoplasms
2875
Carcinoma, Non-Small-Cell Lung
2428
Breast Neoplasms
2068
Colorectal Neoplasms
1247
Neoplasm Metastasis
1232
Prostatic Neoplasms
1080
Melanoma
974
Multiple Myeloma
963
Ovarian Neoplasms
904
Recurrence
852
Leukemia, Myeloid, Acute
810
Lung Neoplasms
758
Pancreatic Neoplasms
753
Lymphoma, Non-Hodgkin
727
Lymphoma
660
Stomach Neoplasms
623
Carcinoma, Hepatocellular
566
Carcinoma, Renal Cell
546
Squamous Cell Carcinoma of Head and Neck
529
Leukemia, Lymphocytic, Chronic, B-Cell
493
Lymphoma, Follicular
468
Head and Neck Neoplasms
451
Glioblastoma
436
Advanced Solid Tumors
432
Small Cell Lung Carcinoma
411
Triple Negative Breast Neoplasms
410
Lymphoma, Large B-Cell, Diffuse
398
Leukemia
394
Uterine Cervical Neoplasms
369
Advanced Solid Tumor
351
Interventions
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Interventional
×
Triple Negative Locally Advanced Non-resectable Breast Cancer
×
Clear all
NCT06827613
2025-09-24
START-002
Marengo Therapeutics, Inc.
Phase 1/2
Recruiting
50 enrolled